Welcome to our dedicated page for ASP Isotopes news (Ticker: ASPI), a resource for investors and traders seeking the latest updates and insights on ASP Isotopes stock.
ASP Isotopes Inc. develops isotope enrichment technologies and related critical-materials businesses for nuclear medicine, next-generation semiconductors, nuclear energy and helium markets. Company news commonly covers its Aerodynamic Separation Process and Quantum Enrichment platforms, enrichment facilities in Pretoria, South Africa, and target isotopes such as Silicon-28, Carbon-14 and Ytterbium-176.
Recurring updates also address PET Labs radiopharmaceutical operations, Quantum Leap Energy nuclear fuel-cycle initiatives, lithium laser enrichment research, Renergen and the Virginia Gas Project, material agreements, governance matters, capital-structure disclosures, and operating and financial results.
ASP Isotopes (NASDAQ: ASPI)/b) announced that Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project in South Africa, has entered the commissioning phase of its Phase 1 liquid helium plant. The project is expected to supply new liquid helium and LNG into a tight global market, with first commercial helium shipments still expected in September and a ramp to nameplate capacity during 2H 2026.According to ASP Isotopes, Phase 1 is expected to produce about 2,500 GJ/day of LNG and 70 Mcf/day of liquid helium, with commercial production targeted for 3Q 2026. Using assumed prices, Renergen is projected to be capable of generating over $27 million in annualized revenue from Phase 1, which ASP Isotopes expects to begin recognizing in 2H 2026. Take-or-pay contracts are signed for roughly 75% of Phase 1 LNG and 15% of liquid helium. Phase 2, planned at about 13 times Phase 1’s size, is expected to start construction in 2H 2026, take around 44 months to build, and is targeted to be funded by up to $750 million of senior debt under discussion with the U.S. International Development Finance Corporation and Standard Bank of South Africa.
ASP Isotopes (NASDAQ: ASPI) announced that its wholly owned subsidiary Quantum Leap Energy (QLE) is evaluating metal conversion opportunities in Namibia. As part of this early-stage assessment, a public environmental and social impact assessment and consultation process has begun for a proposed pilot-scale hydrofluorination and fluorination facility near Walvis Bay.
The pilot facility would be used to develop, test and demonstrate metal hydrofluorination and fluorination processes and remains subject to technical, commercial, environmental and regulatory reviews, with no final investment decision made. QLE focuses on nuclear fuel cycle technologies and holds exclusive global rights to ASP and Quantum Enrichment technologies.
ENDRA Life Sciences (NASDAQ: NDRA) reported second quarter 2026 results and a major strategic shift via a definitive merger agreement signed on June 25, 2026 with Noble Africa, ASP Isotopes (NASDAQ: ASPI), Renergen and others. Noble Africa will merge with a wholly owned ENDRA subsidiary, becoming a wholly owned subsidiary, and ENDRA is expected to be renamed Noble Africa Inc. after closing, targeted for Q4 2026 subject to stockholder and regulatory approvals. In connection with the merger, Noble Africa entered subscription agreements for a private placement expected to raise about $50 million in gross proceeds. ENDRA also completed a separate $3.8 million private placement on May 28, 2026. As of June 30, 2026, ENDRA reported cash of $1.7 million, restricted cash of $3.8 million, digital assets of $1.9 million, other income of $1.6 million mainly from digital asset gains, and net income of about $160,000 versus a $1.2 million loss a year earlier.
ASP Isotopes (NASDAQ: ASPI) announced that Tetra4, a subsidiary of Renergen and developer of the Virginia Gas Project in South Africa, has signed a new five-year take-or-pay LNG sales contract with a domestic food processor. The LNG will be sold on an all-in plant-gate basis at a price of greater than $16 per GJ (0.9478 MMBtu) and represents about 10% of Phase 1 nameplate capacity, which is expected to produce roughly 2,500 GJ/day of LNG and 70 Mcf/day of liquid helium.
Following this agreement, Renergen has secured take-or-pay contracts for about 75% of anticipated Phase 1 LNG volumes. Assuming LNG pricing of $15–18 per GJ and $600/Mcf for helium, ASP Isotopes estimates that Renergen could generate over $27 million in annualized revenue after Phase 1 completion, with commercial production targeted for 3Q 2026 and initial revenue recognition expected in 2H 2026. The company is in active discussions to finalize remaining Phase 1 offtake and start contracting significant Phase 2 volumes in the second half of 2026.
ASP Isotopes (NASDAQ: ASPI) will participate in Citi’s 2026 Natural Resources Conference by hosting investor meetings on Thursday, August 13, 2026, in Las Vegas, Nevada. The company directs investors to its latest investor presentation under the Investors tab on its website.
ASP Isotopes develops proprietary Aerodynamic Separation Process and Quantum Enrichment technologies for isotope enrichment, operating facilities in Pretoria, South Africa. The release also outlines a proposed merger and related transactions among ENDRA Life Sciences, ASP Isotopes, Renergen and Noble Africa, noting that ENDRA plans to file a Form S-4 registration statement with the SEC, which will include a proxy statement and prospectus for ENDRA stockholders.
ASP Isotopes (NASDAQ: ASPI) issued a shareholder letter outlining strong 1H 2026 operating momentum, strategic milestones and long‑term EBITDA targets. PET Labs delivered over 50% organic revenue growth versus 1H 2025 and is forecast to generate about $14 million in FY 2026 revenue, up from $6 million in 2025.
ASPI expects Renergen to commence helium production before September 30, 2026, with Phase 1 helium and LNG revenues projected at roughly $27 million annually and Phase 2 targeted to exceed $360 million in annual revenue at nameplate capacity. Renergen is anticipated to list on Nasdaq via a reverse merger with ENDRA Life Sciences (NDRA), with ASPI initially holding about 89% of the combined company.
Silicon‑28 and Ytterbium‑176 enrichment plants are in late stages toward first shipments in 2H 2026 following earlier equipment‑related delays. ASP Isotopes reiterates a long‑term aspirational EBITDA target of more than $300 million by 2031, driven mainly by PET Labs and Renergen, and continues to pursue separate listings for Quantum Leap Energy and progress Alpa Theranostics toward human clinical trials.
ASP Isotopes (NASDAQ: ASPI) announced that Chief Commercial Officer Viktor Petkov will deliver a company presentation at Canaccord Genuity’s 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00 a.m. ET. A live audio webcast and subsequent replay will be available in the Investors section of the company’s website.
According to ASP Isotopes, it is developing proprietary Aerodynamic Separation Process and Quantum Enrichment technologies and operates isotope enrichment facilities in Pretoria, South Africa. The release also describes proposed merger transactions involving ENDRA Life Sciences, ASP Isotopes, Renergen and Noble Africa, noting that ENDRA plans to file a Form S‑4 registration statement with proxy statement/prospectus and emphasizing that the communication is not an offer or solicitation for any securities.
ASP Isotopes (NASDAQ: ASPI) announced it will hold a Capital Markets Day in London on Tuesday, September 8, 2026, from 10:00 a.m. to 12:30 p.m. ET (3:00 p.m. to 5:30 p.m. BST). Leadership plans to present an update on strategic direction and commercial momentum, with detailed sessions on nuclear medicine, electronic gases, nuclear fuels, and related long-term market opportunities.
In-person attendance is invitation-only, but the public can join via a live webcast with prior registration, with materials and a replay available on the investor relations section of the company’s website. According to ASP Isotopes, the release also highlights a set of proposed merger and related transactions involving ENDRA Life Sciences, ASP Isotopes, Renergen, and Noble Africa, for which ENDRA plans to file a Form S-4 registration statement with the SEC containing a proxy statement and prospectus. Investors are urged to read these documents carefully when available, and the communication clarifies it does not constitute an offer or solicitation for any securities.
ASP Isotopes (NASDAQ: ASPI) announced that its wholly owned subsidiary Quantum Leap Energy (QLE) has signed a research agreement with the Texas A&M Engineering Experiment Station (TEES) to support commercialization of high-purity uranium hexafluoride (UF6), a key feedstock for nuclear fuel enrichment. The collaboration will collect fundamental physicochemical data on converting yellowcake uranium (U3O8) into UF6, with the aim of improving production efficiency, reducing costs, and enhancing scalability. According to the company, the work is expected to inform QLE’s process design, modeling, and scale-up activities, reinforce its uranium conversion technology efforts, and contribute to a more resilient U.S. nuclear fuel supply chain and a stronger nuclear ecosystem in Texas.
ASP Isotopes (NASDAQ:ASPI) and ENDRA Life Sciences (NASDAQ:NDRA) will participate in a RedChip investor webinar on July 21, 2026, at 4:15 p.m. ET, featuring Noble Africa, a wholly owned ASPI subsidiary and holding company for Renergen’s Virginia Gas Project.
The webinar will discuss Noble Africa’s proposed merger with ENDRA, which, if completed, is expected to result in Noble Africa becoming a Nasdaq-listed public company under the ticker “NOBA”. CEO Paul Mann will outline the Virginia Gas Project helium and LNG platform, its planned Phase 1 production ramp in 2026, Phase 2 expansion plans, key operational and financing milestones, and how a proposed Nasdaq listing is expected to support Noble Africa’s long-term growth strategy. A live Q&A session will follow.